FibroGen
Elena Vaisberg is an accomplished Associate Scientist at FibroGen, where experience from May 2011 to the present emphasizes expertise in cell-based assay development and validation for oncology and inflammation programs. Previous roles include Associate Research Scientist II at Exelixis, where validation of oncology targets and development of assays occurred, and Senior Research Associate positions at Threshold Pharmaceuticals and Galileo Pharma, focusing on assay optimization and co-culture model systems in oncology and metabolic disease research. Early career experience includes significant contributions at DNAX Research Institute and as a Research Assistant at the University of Colorado at Boulder, specializing in cell cycle regulation and molecular analysis. Elena Vaisberg holds a Master of Science degree in Biology from Lomonosov Moscow State University.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.